Green Cross sold anti-osteoporosis technology at 160 billion won.

Published: 2006-03-17 06:59:00

Updated: 2006-03-17 06:59:00

For the first time in the history of Korean Green Cross made a technology transfer of an experimental bio drug "rhPTH (recombinant human parathyroid hormone) to Germany at about 160 billion won (Euro dollar 130 million), the agreement of which was signed at the head office located in Yongin Suji ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK